ArticleMolecular cancer therapeutics2022

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.

Magda Bahcall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.